634 related articles for article (PubMed ID: 21870889)
21. In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis.
Granberg T; Fan Q; Treaba CA; Ouellette R; Herranz E; Mangeat G; Louapre C; Cohen-Adad J; Klawiter EC; Sloane JA; Mainero C
Brain; 2017 Nov; 140(11):2912-2926. PubMed ID: 29053798
[TBL] [Abstract][Full Text] [Related]
22. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
Miller DH; Albert PS; Barkhof F; Francis G; Frank JA; Hodgkinson S; Lublin FD; Paty DW; Reingold SC; Simon J
Ann Neurol; 1996 Jan; 39(1):6-16. PubMed ID: 8572668
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients.
Chan JK; Hernandez Martínez de Lapiscina E; Taylor C; Nguyen AL; Alba-Arbalat S; Devonshire V; Sayao AL; Carruthers R; Costello F; Traboulsee A
J Neuroophthalmol; 2020 Mar; 40(1):37-43. PubMed ID: 32045393
[TBL] [Abstract][Full Text] [Related]
24. The role of optical coherence tomography in the diagnosis of afferent visual pathway problems: A neuroophthalmic perspective.
Costello F; Chen JJ
Handb Clin Neurol; 2021; 178():97-113. PubMed ID: 33832689
[TBL] [Abstract][Full Text] [Related]
25. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis.
Zaveri MS; Conger A; Salter A; Frohman TC; Galetta SL; Markowitz CE; Jacobs DA; Cutter GR; Ying GS; Maguire MG; Calabresi PA; Balcer LJ; Frohman EM
Arch Neurol; 2008 Jul; 65(7):924-8. PubMed ID: 18625859
[TBL] [Abstract][Full Text] [Related]
26. [Neurodegeneration and neuroprotection in multiple sclerosis].
Davydovskaia MV; Boĭko AN; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):44-52. PubMed ID: 19891348
[TBL] [Abstract][Full Text] [Related]
27. [Future of non conventional MR techniques in MS].
Pelletier J; Audoin B; Ranjeva JP
Rev Neurol (Paris); 2007 Jun; 163(6-7):663-6. PubMed ID: 17607186
[TBL] [Abstract][Full Text] [Related]
28. New developments in understanding and treating neuroinflammation.
Infante-Duarte C; Waiczies S; Wuerfel J; Zipp F
J Mol Med (Berl); 2008 Sep; 86(9):975-85. PubMed ID: 18196212
[TBL] [Abstract][Full Text] [Related]
29. Recent developments in imaging of multiple sclerosis.
Poloni G; Minagar A; Haacke EM; Zivadinov R
Neurologist; 2011 Jul; 17(4):185-204. PubMed ID: 21712664
[TBL] [Abstract][Full Text] [Related]
30. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
31. Can Optical Coherence Tomography Be Used to Guide Treatment Decisions in Adult or Pediatric Multiple Sclerosis?
Lambe J; Murphy OC; Saidha S
Curr Treat Options Neurol; 2018 Mar; 20(4):9. PubMed ID: 29564662
[TBL] [Abstract][Full Text] [Related]
32. The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis.
Lycke J; Zetterberg H
Expert Rev Clin Immunol; 2017 Dec; 13(12):1143-1153. PubMed ID: 29090607
[TBL] [Abstract][Full Text] [Related]
33. Optical coherence tomography detection of neurodegeneration in multiple sclerosis.
Lidster K; Baker D
CNS Neurol Disord Drug Targets; 2012 Aug; 11(5):518-27. PubMed ID: 22583437
[TBL] [Abstract][Full Text] [Related]
34. Optical Coherence Tomography in Alzheimer's Disease and Other Neurodegenerative Diseases.
Doustar J; Torbati T; Black KL; Koronyo Y; Koronyo-Hamaoui M
Front Neurol; 2017; 8():701. PubMed ID: 29312125
[TBL] [Abstract][Full Text] [Related]
35. Neurodegeneration in multiple sclerosis.
Mey GM; Mahajan KR; DeSilva TM
WIREs Mech Dis; 2023 Jan; 15(1):e1583. PubMed ID: 35948371
[TBL] [Abstract][Full Text] [Related]
36. Axonal loss and neurofilament phosphorylation changes accompany lesion development and clinical progression in multiple sclerosis.
Schirmer L; Antel JP; Brück W; Stadelmann C
Brain Pathol; 2011 Jul; 21(4):428-40. PubMed ID: 21114565
[TBL] [Abstract][Full Text] [Related]
37. [Aiming for zero blindness].
Nakazawa T
Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
[TBL] [Abstract][Full Text] [Related]
38. Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives.
Behl T; Kaur G; Sehgal A; Bhardwaj S; Singh S; Buhas C; Judea-Pusta C; Uivarosan D; Munteanu MA; Bungau S
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573368
[TBL] [Abstract][Full Text] [Related]
39. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.
Barkhof F; van Walderveen M
Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1675-86. PubMed ID: 10603619
[TBL] [Abstract][Full Text] [Related]
40. Neuroaxonal regeneration is more pronounced in early multiple sclerosis than in traumatic brain injury lesions.
Schirmer L; Merkler D; König FB; Brück W; Stadelmann C
Brain Pathol; 2013 Jan; 23(1):2-12. PubMed ID: 22612622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
